Vancouver, BC, Nov 2, 2020 - (ACN Newswire) - BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19.The BioVaxys method is based on measuring an immune response in a human showing no signs or symptoms of an active SARS-CoV-2 infection by administering a skin test of a subunit of the SARS-CoV-2 S-protein. Using Delayed Type Hypersensitivity[1] ("DTH"), a method which is known to demonstrate prior exposure and T cell immunity to tuberculosis[2], the immune system causes an inflammatory response that develops 24 to 72 hours after exposure. This type of immune response involves mainly T-cells rather than antibodies, which are made by B-cells.If ultimately successful, the diagnostic is intended to provide a low-cost, easy-to-administer, and accurate way to test f...